Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 6

recruiting
3 974
countries
28
conditions
2 106

80 trials match your criteria

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

Acute myeloid leukaemia+1

Not recruiting

Study of three different doses of busulfan with fludarabine and thymoglobuline in stem cell transplantation for patients with high-risk myeloid blood disorders

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan

Cervix carcinoma

Not recruiting

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

B-cell lymphoma+1

Not recruiting

Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine

Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Study on the Safety and Effectiveness of AUTO1 for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Using a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Neoplasm malignant

Not recruiting

Study on the Effectiveness of Autologous Tumor-Infiltrating Lymphocytes, Aldesleukin, Fludarabine Phosphate, and Cyclophosphamide in Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.